| Literature DB >> 32435174 |
Charis Girvalaki1,2, Sophia Papadakis1,2,3,4, Enkeleint A Mechili2,5, Katerina Nikitara1,2, Andrey Demin6, Antigona C Trofor7,8, Arben Lila9, Arusyak Harutyunyan10, Aurela Saliaj5, Deska Dimitrievska11, Francisco Rodriguez Lozano1,12, George Bakhturidze13, Javier Ayesta14, Krzysztof Przewoźniak15,16, Maria Sofia Cattaruzza17,18, Marija Zdraveska11, Mihaela Lovše19, Biljana Kilibarda20, Otto Stoyka21, Panagiotis Behrakis22,23, Pierre Bizel24, Polina Starchenko1, Shkumbin Spahija9, Cornel Radu-Loghin1, Constantine I Vardavas1,2.
Abstract
INTRODUCTION: In 2018, the European Network for Smoking Cessation and Prevention (ENSP) released an update to its Tobacco Treatment Guidelines for healthcare professionals, which was the scientific base for the development of an accredited eLearning curriculum to train healthcare professionals, available in 14 languages. The aim of this study was to evaluate the effectiveness of ENSP eLearning curriculum in increasing healthcare professionals' knowledge, attitudes, self-efficacy (perceived behavioral control) and intentions in delivering tobacco treatment interventions in their daily clinical routines.Entities:
Keywords: eLearning; evidence-based strategies; healthcare professionals; smoking cessation
Year: 2020 PMID: 32435174 PMCID: PMC7233524 DOI: 10.18332/tid/120188
Source DB: PubMed Journal: Tob Induc Dis ISSN: 1617-9625 Impact factor: 2.600
Characteristics of healthcare professionals who participated in the ENSP eLearning for treating tobacco dependence
| Male | 118 | 26.6 |
| Female | 326 | 73.4 |
| <30 | 193 | 43.5 |
| 30–39 | 85 | 19.1 |
| 40–49 | 93 | 20.9 |
| 50–59 | 48 | 10.8 |
| 60–69 | 24 | 5.4 |
| ≥70 | 1 | 0.2 |
| Private | 116 | 26.1 |
| Public | 328 | 73.9 |
| Urban | 363 | 81.9 |
| Suburban | 45 | 10.2 |
| Rural | 35 | 7.9 |
| Part-time | 80 | 18.0 |
| Full-time | 364 | 82.0 |
| Yes | 138 | 31.1 |
| No | 306 | 68.9 |
| Smoker | 33 | 7.4 |
| Ex-smoker | 110 | 24.8 |
| Non-smoker | 301 | 67.8 |
| Process to screen and document smoking status of patients | 242 | 56.5 |
| Self-help materials for smokers | 120 | 28.0 |
| Consult forms to guide through quit smoking counselling interventions | 66 | 15.4 |
Proportion of trainees who responded correctly to knowledge assessment at the pre- and post-assessments
| For most smokers, tobacco use is… | 186 (42.3) | 394 (89.5) | 0.420–0.525 | <0.001 |
| Nicotine is as addictive as other drugs such as heroin or cocaine. | 350 (79.5) | 424 (96.4) | 0.129–0.208 | <0.001 |
| Which of the following are common withdrawal symptoms experienced when someone quits smoking? | 369 (83.9) | 432 (98.2) | 0.107–0.179 | <0.001 |
| How soon may someone begin to experience withdrawal symptoms when they go without a cigarette? | 149 (33.9) | 386 (87.7) | 0.482–0.595 | <0.001 |
| Which of the following are not true about nicotine withdrawal symptoms? | 192 (43.6) | 373 (84.8) | 0.356–0.466 | <0.001 |
| What proportion of smokers report night wakening or difficulty sleeping after they quit? | 230 (52.3) | 417 (94.8) | 0.373–0.477 | <0.001 |
| The majority of patients who quit smoking experience irritability, restlessness, and depression? | 332 (75.5) | 420 (95.5) | 0.157–0.243 | <0.001 |
| Which of the following are not true about people who are fast nicotine metabolizers? | 311 (70.8) | 419 (95.4) | 0.198–0.294 | <0.001 |
| What are the most common reasons people return to smoking in the first few weeks after quitting? | 336 (76.4) | 428 (97.3) | 0.166–0.252 | <0.001 |
| People who quit smoking will have more, less, or the same amount of stress? | 185 (42.0) | 399 (90.5) | 0.434–0.537 | <0.001 |
| Tobacco treatment should be delivered with the same rigor and clinical importance as any other major chronic risk factor. | 418 (94.6) | 436 (98.6) | 0.019–0.062 | <0.001 |
| A clinician’s advice to quit is not very effective in motivating patients to quit. | 327 (74.0) | 425 (96.2) | 0.176–0.268 | <0.001 |
| Advice to quit smoking should be… | 348 (78.7) | 429 (97.1) | 0.143–0.223 | <0.001 |
| Offering patients your support with quitting has been shown to increase patient motivation to quit. | 409 (92.5) | 439 (99.3) | 0.042–0.094 | <0.001 |
| If a patient informs you they are not ready to quit, what should you do? | 396 (89.6) | 437 (98.9) | 0.064–0.122 | <0.001 |
| Which of the following questions are important pieces of information gathered as part of the smoking history? (check all that are correct) | 382 (86.4) | 435 (98.4) | 0.086–0.153 | <0.001 |
| Which of the following are important pieces of information to discuss with patients when developing a motivational intervention or personalized quit plan? | 383 (86.8) | 434 (98.4) | 0.082–0.149 | <0.001 |
| Patients that have higher levels of nicotine dependence can be assessed by… | 262 (59.3) | 390 (88.2) | 0.236–0.344 | <0.001 |
| For patients who report they are interested in quitting smoking, evidence has shown that the most effective evidence-based treatments are… | 324 (73.3) | 418 (94.6) | 0.170–0.255 | <0.001 |
| It is recommended that follow-up be scheduled 2–8 weeks, following the patient’s initial consultation, to review progress and response to therapy and make any adjustments to the plan. | 371 (84.3) | 432 (98.2) | 0.102–0.176 | <0.001 |
| Which of the following are not true about follow-up support for individuals who are quitting smoking? | 301 (68.3) | 414 (93.9) | 0.209–0.303 | <0.001 |
| The main goals of behavioral counselling are to… | 349 (79.0) | 419 (94.8) | 0.117–0.199 | <0.001 |
| There is no evidence that counselling helps patients to quit smoking. | 365 (82.6) | 429 (97.1) | 0.107–0.183 | <0.001 |
| Which of the following are true? | 385 (87.3) | 430 (97.5) | 0.070–0.134 | <0.001 |
| How long does a craving typically last? | 231 (52.3) | 426 (96.4) | 0.392–0.490 | <0.001 |
| The 4Ds strategies are the recommended approach for dealing with cravings to smoke and include. | 319 (73.0) | 427 (97.7) | -1.397–0.985 | 0.734 |
| Recent quitters are still vulnerable to relapse, especially in the first three to six months after quitting. | 412 (93.2) | 428 (96.8) | 0.007–0.066 | 0.016 |
| Motivational interviewing is… | 233 (52.8) | 394 (89.3) | 0.311–0.419 | <0.001 |
| The goal of motivational interviewing is not necessarily to get the patients to change but rather to get the patient talking and thinking about changing their smoking behavior. | 353 (80.0) | 436 (98.6) | 0.150–0.226 | <0.001 |
| Motivational interviewing techniques clinicians should use, include… | 358 (81.0) | 431 (97.5) | 0.127–0.203 | <0.001 |
| Developing discrepancy between a patient’s current behavior and expressed priorities, values and goals is a strategy used as part of motivational interviewing. This can be done by… | 180 (40.7) | 344 (77.8) | 0.117–0.199 | <0.001 |
| Are nicotine replacement therapies contraindicated for people with cardiovascular disease? | 318 (72.6) | 426 (97.3) | 0.203–0.290 | <0.001 |
| Is it safe to continue to smoke while using nicotine replacement therapy? | 201 (45.7) | 427 (97.0) | 0.464–0.563 | <0.001 |
| Nicotine replacement therapy should only be used for a maximum of 12 weeks. | 244 (55.5) | 399 (90.7) | 0.299–0.406 | <0.001 |
| You may use any form of nicotine replacement therapy alone but they should not be used in combination. | 248 (56.5) | 431 (98.2) | 0.369–0.465 | <0.001 |
| A patient smokes 1 pack of cigarettes per day and smokes within 5 minutes of waking in the morning. What dose of NRT should he be started on? | 206 (46.8) | 342 (77.7) | 0.255–0.363 | <0.001 |
| A patient is using NRT but reports severe cravings and is concerned he/she may return to smoking. What do you recommend? | 244 (55.5) | 402 (91.4) | 0.307–0.411 | <0.001 |
| A woman using Bupropion reports a variety of side effects since beginning the medication. What do you recommend to address this issue? | 242 (55.0) | 396 (90.0) | 0.298–0.402 | <0.001 |
| Bupropion is contraindicated among… (Click all that apply) | 353 (80.2) | 427 (97.0) | 0.128–0.208 | <0.001 |
| What is the most common side effects of Varenicline? | 300 (68.5) | 425 (96.2) | 0.232–0.325 | <0.001 |
| Which of the following strategies can be used for patients who report experiencing nausea while using Varenicline? | 229 (52.0) | 378 (85.9) | 0.280–0.397 | <0.001 |
| Patients using Varenicline should be advised to quit smoking how many weeks after using the treatment? | 22 (50.9) | 339 (77.0) | 0.206–0.317 | <0.001 |
| For patients using Varenicline who experience vivid dreams it can be recommended that they… | 333 (75.9) | 428 (97.5) | 0.175–0.258 | <0.001 |
| It is safe to use Varenicline for 6-month period or longer? | 247 (56.3) | 371 (84.5) | 0.225–0.340 | <0.001 |
| Which are the most effective medications in terms of increasing success rates | 355 (80.7) | 433 (98.4) | 0.139–0.216 | <0.001 |
Multiple choice questions.
95% confidence interval of difference between pre- and post-assessments.
McNemar-Bowker test.
Self-reported attitudes, normative beliefs, perceived behavioral control and intention changes of the healthcare professionals that participated in the ENSP eLearning for treating tobacco dependence
| Counseling by a clinician helps motivate smokers to quit. | 5.0 (1.0) | 4.0 – 5.0 | 5.0 (0.0) | 5.0 – 5.0 | -7.370 | <0.001 |
| For many tobacco users smoking is an addiction. | 5.0 (1.0) | 4.0 – 5.0 | 5.0 (1.0) | 4.0 – 5.0 | -2.820 | 0.005 |
| First line pharmacotherapies for smoking cessation work well in helping patients quit. | 3.0 (1.0) | 3.0 – 4.0 | 5.0 (1.0) | 4.0 – 5.0 | -13.243 | <0.001 |
| First line pharmacotherapies for smoking cessation have side effects that outweigh their benefits. | 2.0 (2.0) | 1.0 – 3.0 | 1.0 (2.0) | 1.0 – 3.0 | -4.265 | <0.001 |
| Tobacco use is killing too many people. | 5.0 (1.0) | 4.0 – 5.0 | 5.0 (0.0) | 5.0 – 5.0 | -1.390 | 0.164 |
| It is my usual practice to assist my patients to quit smoking. | 4.0 (2.0) | 4.0 – 5.0 | 4.0 (1.0) | 4.0 – 5.0 | -5.346 | <0.001 |
| Smoking cessation is an important part of my role as a healthcare professional. | 5.0 (1.0) | 4.0 – 5.0 | 5.0 (0.0) | 5.0 – 5.0 | -5.316 | <0.001 |
| Smoking is a personal decision which does not concern the healthcare professional. | 1.0 (2.0) | 1.0 – 3.0 | 1.0 (2.0) | 1.0 – 3.0 | -0.360 | 0.719 |
| Healthcare professionals should advise patients to quit smoking even if it is not the reason for the visit. | 5.0 (1.0) | 4.0 – 5.0 | 5.0 (0.0) | 5.0 – 5.0 | -2.562 | 0.010 |
| Healthcare professionals should make appointments specifically to help patients quit. | 5.0 (2.0) | 3.0 – 5.0 | 5.0 (1.0) | 4.0 – 5.0 | -5.096 | <0.001 |
| A patient’s will power alone is what will determine their success with quitting. | 4.0 (1.0) | 2.0 – 4.0 | 3.0 (2.0) | 2.0 – 4.0 | -2.968 | 0.003 |
| I have the required skills to help my patients quit smoking. | 3.0 (2.0) | 2.0 – 4.0 | 4.0 (1.0) | 4.0 – 5.0 | -13.083 | <0.001 |
| I do not feel I have effective methods to assist my patients with quitting. | 3.0 (2.0) | 2.0 – 4.0 | 2.0 (2.0) | 1.0 – 3.0 | -7.949 | <0.001 |
| My patients follow my advice about behavior change. | 3.0 (1.0) | 3.0 – 4.0 | 4.0 (2.0) | 3.0 – 5.0 | -11.256 | <0.001 |
| My patients who smoke want to quit smoking. | 3.0 (1.0) | 3.0 – 4.0 | 4.0 (2.0) | 3.0 – 5.0 | -6.931 | <0.001 |
| I know where to refer patients for help with smoking cessation. | 4.0 (3.0) | 4.0 – 5.0 | 5.0 (1.0) | 4.0 – 5.0 | -10.388 | <0.001 |
| Address tobacco use with all my patients as priority. | 4.0 (2.0) | 3.0 – 5.0 | 5.0 (1.0) | 4.0 – 5.0 | -4.414 | <0.001 |
| Document tobacco use status in the patient’s medical record. | 5.0 (2.0) | 3.0 – 5.0 | 5.0 (1.0) | 4.0 – 5.0 | -6.703 | <0.001 |
| Offer my support to all my patients making a quit attempt. | 5.0 (1.0) | 4.0 – 5.0 | 5.0 (0.0) | 5.0 – 5.0 | -7.022 | <0.001 |
| Provide brief smoking cessation counseling (3–5 minutes). | 5.0 (1.0) | 4.0 – 5.0 | 5.0 (0.0) | 5.0 – 5.0 | -5.586 | <0.001 |
| Give my patients written materials about quitting smoking. | 5.0 (2.0) | 3.0 – 5.0 | 5.0 (1.0) | 4.0 – 5.0 | -4.719 | <0.001 |
| Discuss available quit-smoking medications with my patients who smoke. | 4.0 (2.0) | 3.0 – 5.0 | 5.0 (1.0) | 4.0 – 5.0 | -9.726 | <0.001 |
| Prescribe a quit smoking medication for patients ready to quit. | 4.0 (3.0) | 2.0 – 5.0 | 5.0 (1.0) | 4.0 – 5.0 | -8.345 | <0.001 |
| Schedule dedicated appointment to develop quit plans with my patients. | 4.0 (2.0) | 3.0 – 5.0 | 5.0 (1.0) | 4.0 – 5.0 | -7.327 | <0.001 |
| Be persistent in addressing tobacco use with my patients even if I am not effective the first time. | 5.0 (1.0) | 4.0 – 5.0 | 5.0 (0.0) | 5.0 – 5.0 | -5.911 | <0.001 |
| 10.0 (1.0) | 9.0 – 10.0 | 10.0 (0.0) | 10.0 - 10.0 | -4.731 | <0.001 |
On a scale from 1 to 5 (strongly disagree to strongly agree).
On a scale from 1 to 10.
Based on negative ranks.
Based on positive ranks.
IQR: interquartile range.
Post period: missing data n=2.